MPM Capital raises $400M in seventh venture fund
The company plans to invest the money across several therapeutic areas and modalities, including oncology, immunology, gene and cell therapies.
5AM raises nearly $500M in two new biotech venture funds
The venture capital firm said Wednesday that it had closed the two new funds - 5AM Ventures VI and 5AM Opportunities I - that will respectively be used for new investments and existing portfolio companies.
Heard at HLTH 2024: Insights from Innovative Healthcare Executives
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence
The New York-based company has two programs in preclinical discovery, based on research conducted at Mount Sinai's Tisch Cancer Institute.
Biopharma startup financing had strong showing in 2018, report shows
The report, by PitchBook, shows figures consistent with a similar report earlier this month by Silicon Valley Bank, which forecast more M&A deals this year.
Atlas Venture raises $250M for Opportunity Fund
The biotech venture capital firm said it plans to invest the money into existing portfolio companies. Several other VC firms have also announced new funds in the last several months.
Relay Therapeutics hits VC jackpot with $400M Series C round for protein motion drug discovery
The round, led by SoftBank Vision Fund, is more than six times the size of Relay's Series B round, which it closed in December 2017.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Versant raises $100M for new Canada fund on top of $600M for global biotech startups
The firm said both funds exceeded their initial targets. Versant plans to use Fund VII for at least 20 global biotech companies, while Versant Voyageurs I will be used to fund five to eight startups with Canadian operations.
Mission Bio raises $30M in Series B round to develop genomics platform
The company said it would use the funding to expand its single-cell DNA sequencing platform into CRISPR applications and global markets.
Aro Biotherapeutics draws $13M in startup investment to target centyrin proteins
The company currently has a product candidate in the late-discovery phase, an EGFR-targeting drug for lung cancer that would go after a resistance mechanism against existing kinase inhibitors.
Versant launches Black Diamond Therapeutics with $20M to pursue untapped cancer mutations
The company plans to file an IND for its allosteric HER2-targeting drug at the end of 2019, followed by one for its second product candidate in the first half of 2020.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
XyloCor closes $17M Series A round to develop gene therapy for refractory angina
The Philadelphia-based company has an IND open with the FDA and plans to begin its clinical trial in the first half of next year.
China’s Alphamab raises $100M in Series A financing from US, Asian investors
The Suzhou-based firm plans to use the money to advance its therapies, currently in clinical development in China and Australia.
Biomatics Capital raises $300M for new fund, hires partner from Gates Foundation
The new fund follows a $200 million fund raised two years ago and will go to diagnostics, therapeutics, R&D and clinical care. New partner Mike Pool will be focused on neuroscience investments.
Life sciences VC investment trends similar to tech, but there are differences
Deals worth $50 million or more are becoming more frequent, even in Series A. But a VC investor said underlying drivers in life sciences are different from the technology sector.
ARCH Venture Partners looks to raise $600M in its 10th fund
The Chicago-based life sciences venture capital firm had previously raised $408.4 million for its ninth fund, in 2016. Others - including Pfizer and Taiho - have recently boosted their VC investment pools as well.